MAPT mRNA (RNAi/ASO)

Assets acting on this target.

Class
Tau (MAPT)-lowering RNAi/antisense oligonucleotide

MAPT is the gene encoding tau, a protein normally found in neurons where it binds and stabilizes microtubules, the internal scaffolding that supports axonal shape and enables transport of cargo along nerve cells. In a group of neurodegenerative diseases known as tauopathies, which include Alzheimer's disease and several frontotemporal dementias, tau becomes abnormally modified and detaches from microtubules, then misfolds and aggregates into insoluble filaments. These aggregates are thought to spread from neuron to neuron and to correlate closely with regional neuronal loss and cognitive decline, making tau a central therapeutic target. Rather than trying to clear existing aggregates directly, RNA interference (RNAi) and antisense oligonucleotide (ASO) approaches work upstream, at the level of gene expression: they bind the MAPT messenger RNA and trigger its degradation or block its translation, reducing production of new tau protein. Because much of the pathological process depends on continuous synthesis of tau available to misfold, lowering total tau supply is proposed to slow the accumulation of toxic species and reduce the substrate available for cell-to-cell spread. This approach is being explored broadly across tauopathies, where disease severity and progression often track with tau pathology burden rather than with amyloid or other co-existing markers.

By indication

Related mechanisms

MAPT mRNA (RNAi/ASO) drugs compared

6 drugs, stage by indication
6 drugs acting on MAPT mRNA (RNAi/ASO): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
NIO752Novartisantisense oligonucleotidePhase 3Phase 3 in Progressive Supranuclear Palsy; Phase 1 in Alzheimer's Disease
DiranersenBiogen, Ionis PharmaceuticalsOligonucleotide (ASO)Phase 2Phase 2 in Alzheimer's Disease
ARO-MAPT-SCArrowhead PharmaceuticalsOligonucleotide (RNAi)Phase 1/2Phase 1/2 in Alzheimer's Disease
ALN-5288Alnylam Pharmaceuticals, Regeneron PharmaceuticalsOligonucleotide (siRNA)Phase 1Phase 1 in Alzheimer's Disease
DNL628Denali TherapeuticsOligonucleotide (ASO)Phase 1Phase 1 in Alzheimer's Disease
LY3954068Eli LillyOligonucleotide (siRNA)Phase 1Phase 1 in Alzheimer's Disease

← all mechanisms